Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Biography

Meet Our Editorial Board Member

Author(s): Peng Zhan

Volume 28, Issue 5, 2021

Published on: 01 April, 2021

Page: [853 - 853] Pages: 1

DOI: 10.2174/092986732805210401144635

« Previous Next »
[1]
Zhao T, Meng Q, Sun Z, et al. Novel human urate transporter 1 inhibitors as hypouricemic drug candidates with favorable druggability. J Med Chem 2020; 63(19): 10829-54.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00223] [PMID: 32897699]
[2]
Xiu S, Dick A, Ju H, et al. Inhibitors of SARS-CoV-2 entry: current and future opportunities. J Med Chem 2020; 63(21): 12256-74.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00502] [PMID: 32539378]
[3]
Sun L, Dick A, Meuser ME, et al. Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities. J Med Chem 2020; 63(9): 4790-810.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00015] [PMID: 32298111]
[4]
Kang D, Feng D, Sun Y, et al. Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties. J Med Chem 2020; 63(9): 4837-48.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00117] [PMID: 32293182]
[5]
Kang D, Ruiz FX, Feng D, et al. Discovery and characterization of fluorine-substituted diarylpyrimidine derivatives as novel HIV-1 NNRTIs with highly improved resistance profiles and low activity for the hERG ion channel. J Med Chem 2020; 63(3): 1298-312.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01769] [PMID: 31935327]
[6]
Wu G, Zhao T, Kang D, et al. Overview of recent strategic advances in medicinal chemistry. J Med Chem 2019; 62(21): 9375-414.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00359] [PMID: 31050421]
[7]
Zhan P, Kang D, Liu X. Resurrecting the condemned: identification of n-benzoxaborole benzofuran GSK8175 as a clinical candidate with reduced metabolic liability. J Med Chem 2019; 62(7): 3251-3.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00415] [PMID: 30916967]
[8]
Huang B, Chen W, Zhao T, et al. Exploiting the tolerant region i of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against wild-type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J Med Chem 2019; 62(4): 2083-98.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01729] [PMID: 30721060]

Rights & Permissions Print Cite
Article Metrics
3
1
© 2024 Bentham Science Publishers | Privacy Policy